ReviewFrontiers in pharmacology2022
Emerging Bismuth Chalcogenides Based Nanodrugs for Cancer Radiotherapy.
Review in Frontiers in pharmacology, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 13 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
13 citing papers in PubMed, 26 citations in OpenAlex.
- Enhancing radiotherapy-induced anti-tumor immunity via nanoparticle-mediated STING agonist synergy.Molecular cancer · 2025Review
- Nanomaterials in Targeting Cancer Cells with Nanotherapeutics: Transitioning Towards Responsive Systems.Current pharmaceutical design · 2024Review
- Nanoarchitectonics of copper sulfide nanoplating for improvement of computed tomography efficacy of bismuth oxide constructs toward drugless theranostics.Regenerative biomaterials · 2024Article
- Recent Advances in Biomimetic Nanocarrier-Based Photothermal Therapy for Cancer Treatment.International journal of molecular sciences · 2023Review
- Emerging Sonodynamic Therapy-Based Nanomedicines for Cancer Immunotherapy.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2023Review
- Microfluidic Synthesis of the Tumor Microenvironment-Responsive Nanosystem for Type-I Photodynamic Therapy.Molecules (Basel, Switzerland) · 2022Article
- Nucleus-Targeting Phototherapy Nanodrugs for High-Effective Anti-Cancer Treatment.Frontiers in pharmacology · 2022Review
- Epigallocatechin-3-gallate Mo nanoparticles (EGM NPs) efficiently treat liver injury by strongly reducing oxidative stress, inflammation and endoplasmic reticulum stress.Frontiers in pharmacology · 2022Article
- Nanodrugs Detonate Lysosome Bombs.Frontiers in pharmacology · 2022Review
- Smart Nanoparticles for Breast Cancer Treatment Based on the Tumor Microenvironment.Frontiers in oncology · 2022Review
- Injectable Hydrogel System for Camptothecin Initiated Nanocatalytic Tumor Therapy With High Performance.Frontiers in oncology · 2022Article
- Nanodrugs Manipulating Endoplasmic Reticulum Stress for Highly Effective Antitumor Therapy.Frontiers in pharmacology · 2022Review
- Current Progress in Cancer Treatment Using Nanomaterials.Frontiers in oncology · 2022Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Radiotherapy (RT), as one of the main methods of clinical tumor treatment, has been applied to the treatment of most solid tumors. However, the effect of RT is compromised by the radiation resistance of tumor hypoxic environment and non-specific damage caused by high-dose radiation. Bismuth chalcogenides (Bi
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.